AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.650
-0.010 (-0.38%)
Feb 21, 2025, 4:00 PM EST - Market closed
AC Immune Employees
As of December 31, 2023, AC Immune had 161 total employees, including 133 full-time and 28 part-time employees. The number of employees increased by 5 or 3.21% compared to the previous year.
Employees
161
Change (1Y)
5
Growth (1Y)
3.21%
Revenue / Employee
$301,276
Profits / Employee
-$293,114
Market Cap
262.19M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ACIU News
- 3 months ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 7 months ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 7 months ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 7 months ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire
- 9 months ago - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 - GlobeNewsWire
- 10 months ago - Alzheimer's vaccine licensing deal boosts AC Immune - Market Watch
- 10 months ago - AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 10 months ago - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease - Business Wire